Patient-reported outcomes essential to comparative effectiveness research

October 16, 2012

Patient-reported outcomes should be a standard part of evaluating the comparative effectiveness of cancer treatments, according to recommendations put forward by a multi-institution research group.

In an early release article published this week online in the , a research group led by Ethan Basch, MD, Director of the Outcomes Research Program at UNC Lineberger Comprehensive Cancer Center, recommends that patient-reported symptoms and health-related quality of life measures should be assessed in comparative effectiveness studies designed to generate new evidence about cancer treatment. The article was written on behalf of the Center for Medical Technology Policy in Baltimore, MD.

Comparative is designed to inform health-care decisions by providing evidence on the effectiveness, benefits, and harms of different treatment options. The evidence is generated from research studies that compare drugs, medical devices, tests, surgeries, or ways to deliver health care.

" research looks at how treatment options perform in a real-world setting, and is particularly important in , where patients are not only fighting their disease but also enduring treatments that may have a significant impact on their ability to function and their quality of life," said Basch.

"There is no way to adequately assess a treatment's impact on the patient without including their point of view, gleaned directly from asking about their experience in a consistent and scientifically-validated manner. Without this information, stakeholders – including patients, physicians and nurses, payers, researchers and regulators – have incomplete information for decision making about a given treatment."

The group recommends evaluation of a set of twelve core symptoms in studies in advanced or , use of standard, validated measurements for patient-reported outcomes, to identify specific symptoms that may be relevant in studies of treatment for particular forms of cancer, and methods to gather the relevant data efficiently and effectively.

Explore further: Strategies proposed to improve impact of comparative effectiveness studies

Related Stories

Strategies proposed to improve impact of comparative effectiveness studies

October 9, 2012
Comparative effectiveness research conducted over the past decade has had a limited impact on the way medical care is delivered, but many opportunities exist to help doctors and others in the medical system translate such ...

Complementary medicine not tied to prostate cancer outcome

May 4, 2012
(HealthDay) -- Although widely used, complementary and alternative medicine (CAM) does not impact patient satisfaction with treatment or patient-reported outcomes after treatment for localized prostate cancer, according to ...

Intensity Modulated Radiation Therapy optimal for localized prostate cancer

April 17, 2012
A treatment for localized prostate cancer known as Intensity Modulated Radiation Therapy (IMRT) is better than conventional conformal radiation therapy (CRT) for reducing certain side effects and preventing cancer recurrence, ...

Cancer survivorship research must look at quality of life: report

October 28, 2011
Assessing the quality of life experienced by cancer survivors is becoming increasingly important, say researchers at Moffitt Cancer Center in Tampa, Fla. Such an assessment has a number of important applications when doing ...

Recommended for you

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.